MARTINSRIED/MUNICH (Germany), Feb. 28 /PRNewswire-FirstCall/ -- WALTHAM, Mass. and PRINCETON, N.J., -- GPC Biotech AG today announced that the Company will give a corporate presentation at the upcoming Cowen & Co. 26th Annual Health Care Conference in Boston, MA as well as at the Ninth Annual Lehman Brothers Global Healthcare Conference in Miami, FL.
The presentation at the Cowen & Co. 26th Annual Health Care Conference will take place on Tuesday, March 7, 2006 at 8 AM EST at The Boston Marriott Copley Place in Boston, MA.
The presentation at the Ninth Annual Lehman Brothers Global Healthcare Conference is scheduled for Wednesday, March 8, 2006 at 9 AM EST at the Loews Miami Beach Hotel in Miami, Florida.
The company presentations at both conferences will be webcast live and will be accessible through the GPC Biotech Web site at http://www.gpc-biotech.com. A replay will also be available via the Web site.
GPC Biotech AG is a biopharmaceutical company discovering and developing new anticancer drugs. The Company’s lead product candidate -- satraplatin -- has achieved target enrollment in a Phase 3 registrational trial as a second- line chemotherapy treatment in hormone-refractory prostate cancer. The U.S. FDA has granted fast track designation to satraplatin for this indication, and GPC Biotech has begun the rolling NDA submission process for this compound. GPC Biotech is also developing a monoclonal antibody with a novel mechanism- of-action against a variety of lymphoid tumors, currently in Phase 1 clinical development, and has ongoing drug development and discovery programs that leverage its expertise in kinase inhibitors. GPC Biotech AG is headquartered in Martinsried/Munich (Germany). The Company’s wholly owned U.S. subsidiary has sites in Waltham, Massachusetts and Princeton, New Jersey. For additional information, please visit the Company’s Web site at http://www.gpc-biotech.com.
For further information, please contact: GPC Biotech AG Martin Braendle Associate Director, Investor Relations & Corporate Communications Phone: +49 (0)89 8565-2693 ir@gpc-biotech.com In the U.S.: Laurie Doyle Associate Director, Investor Relations & Corporate Communications Phone: +1 781-890-9007 X267 usinvestors@gpc-biotech.com
GPC Biotech AG
CONTACT: Martin Braendle, Associate Director, Investor Relations &Corporate Communications, +49 (0)89 8565-2693, ir@gpc-biotech.com, orLaurie Doyle, Associate Director, Investor Relations & CorporateCommunications, +1- 781-890-9007, ext. 267, usinvestors@gpc-biotech.com,both of GPC Biotech AG
Web site: http://www.gpc-biotech.com/
